$195 On-Demand Access Pass Available Now!

*Virtual events will take place in Eastern Standard Time*

Virtual Coffee Talk

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match making services.

Introduction to the Virtual Event Platform & Sharing of the Summit’s Mission

Ben Greenzweig | CEO, Co-Founder | Momentum Events

Co-Chair’s Opening Remarks

    • Colin Beattie | Founder and CEO | Entheos
    • Debra Borchardt | CEO, Co-Founder | Green Market Report

Opening Keynote: An Introduction to the Latest Research and Findings on the Therapeutic Effects of the Psychedelic Compound Psilocybin from the leading psychedelic research institution, Johns Hopkins.

In 2000, the research group at Johns Hopkins was the first to obtain regulatory approval in the United States to reinitiate research with psychedelics in healthy volunteers. Since then, it has published groundbreaking studies in more than 60 peer-reviewed articles in respected scientific journals, making Johns Hopkins the leading psychedelic research institution in the U.S. One of the leading researchers at Hopkins’ Center for Psychedelic and Consciousness Research is Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, an expert on psychedelics, other drugs, and addiction. He has conducted research in behavioral pharmacology for more than 20 years and with psychedelics for more than 15 years. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in treating cancer distress in 2016. His 2018 review of psilocybin abuse liability recommended placement in Schedule-IV upon potential medical approval. Matt has been interviewed widely about drugs, addiction, and risk behavior, including by the New York Times, Washington Post, Wall Street Journal, BBC, 60 Minutes, CNN, Fox Business News, NPR, CBS News, and NBC News.

Key Takeaways:

  • Understand the latest findings of psychedelic research
  • Gain insight into practical, long term applications of psychedelic therapies
  • Matthew W. Johnson, Ph.D. | Professor of Psychiatry and Behavioral Sciences | Johns Hopkins University School of Medicine

Keynote Roundtable: A Holistic View of the Current State of Psychedelic Affairs, Research, Trials, and Conclusions from Leading Researchers

After spending decades in the shadows, psychedelics have slowly reemerged as an effective treatment option for a wide variety of health issues including depression, anxiety, PTSD and addiction. This session will provide a complete update on the research and applications of psychedelics from several leading authorities, and provide the audience with the opportunity to ask the questions and engage directly with the researchers on the front lines.


 
  • Key Takeaways:
  • Understand the latest research and findings on psychedelics and drug addiction from leading scientist from Johns Hopkins and the University of Alabama School of Public Health
  • Gain insight into the latest research on psychedelics for addiction, end of life and behavioral health
  • Participate in an interactive discussion with some of the leading researchers on psychedelics
  • Matthew W. Johnson, Ph.D. | Professor of Psychiatry and Behavioral Sciences | Johns Hopkins University School of Medicine
  • Peter S. Hendricks, PhD. | Associate Professor | University of Alabama at Birmingham School of Public Health

Morning Break

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.

Why the Pathway for Psychedelics is and will Remain Drastically Different than Cannabis

While the seeds of the 21st century cannabis decriminalization movement sprung from the medical promises and applications, the rapid growth of this sector has been highly concentrated in the recreational economy; whereas psychedelics have (re)emerged from a completely therapeutic perch. With a legal framework already established for clinical research and development, there numerous ways that psychedelics differ from cannabis from a regulatory perspective, and access to funding seems to be the only significant barrier.

  • Key Takeaways:
  • Understand the current US and international legal framework for psychedelic research, development and applications
  • Recognize the regulatory differences between cannabis and psychedelics and what it means for investment opportunities
  • Gain insight into what the potential future legal pathway might look like for this class of drugs so you can strategize accordingly
    • David Feldman | Partner | Hiller PC
    • Benton B. Bodamer| Member | Dickinson Wright PLLC

Morning Session End

Virtual Lobby Open

Industry Keynote Address: Accelerating Patient Access with Compass Pathways

How do you progress research, development and deployment of effective psychedelic therapy to as many people in need, as quickly and safely as possible? Navigating long-standing best practices with drug development under the best of circumstance can be challenging, so how do you manage such a process when the compounds in question remain for the most part, illegal, while ensuring the most successful possible outcomes for patients? In the absence of historical precedent, learn how COMPASS Pathways is writing its own playbook for the research and development of psychedelic behavioral therapies in order to drive safe, affordable and timely access for those who need it most.

  • Gain insight into COMPASS Pathways’ approach to the development of psilocybin therapy for treatment-resistant depression
  • Understand the path from drug to medicine
  • Learn how this company is driven to provide safe, affordable and timely access to psilocybin therapy
  • George Goldsmith | Executive Chairman, Chief Executive Officer and Co-Founder | COMPASS Pathways

Navigating Complication, Difficulty and Regulation: How to Effectively Run Clinical Trials with a Psychedelic and Therapy Support

Ensuring evidence-based treatment for psychedelics is critical, but how can companies effectively run clinical trials across multiple geographies that are consistent with the highest standards of conduct when the medicine in question is culturally disruptive and legally uncertain based on jurisdiction?

  • Key Takeaways:
  • Gain the perspective of for-profit and non-profit approaches towards psychedelic investment, research and development
  • Learn how these leading organizations manage an immensely complicated process, from funding to development, trials to application
  • Ekaterina Malievskaia MD MScPH | Chief Innovation Officer and Co-Founder | Compass Pathways
  • Berra Yazar-Klosinski, Ph.D | Deputy Director and Head of Research Development and Regulatory Affairs | MAPS Public Benefit Corporation

Regulatory Keynote Address: Perspectives from the Food and Drug Administration on Psychedelics: History of Human Studies, Current Clinical Trial Design Considerations, and Assessing Their Abuse Potential

  • Katherine Bonson, Ph.D. Senior Pharmacologist Controlled Substance Staff Office of the Center Director The Center for Drug Evaluation and Research (CDER)/ U.S. Food and Drug Administration (FDA)
  • Javier A. Muniz, MD Associate Director Division of Psychiatry Office of Neuroscience The Center for Drug Evaluation and Research (CDER)/ U.S. Food and Drug Administration (FDA)

Afternoon Break

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services

Where the Rubber Meets the Road – Theoretical Incorporation of Psychedelic Treatment into the US Payer Ecosystem: What Can This Look Like?

From the billing and coding code to revenue and reimbursement, what foundation could be developed in order to offer psychedelic treatment for behavioral health ailments that are considered routine conventional care?

  • Key Takeaways:
  • Explore the current and future state of payer coverage
  • Understand the challenges and opportunities of the ecosystem
  • Gain the insights needed to build your reimbursement toolbox
  • Kelly Willenberg | President | Kelly Willenberg & Associates

Day 1 Concludes

Virtual Coffee Talk!

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.

(Re)introduction to the Virtual Event Platform

  • Ben Greenzweig | CEO, Co-Founder | Momentum Events

Co-Chair’s Opening Remarks

 

  • Colin Beattie | Founder and CEO | Entheos
  • Debra Borchardt | CEO, Co-Founder | Green Market Report

Current Barriers and Innovations in Mental Health Care: Developing a More Efficient and Effective Model for Therapeutic Delivery Across a Range of Modalities

You can’t discuss the application of psychedelics without discussing the method of delivery and economics; specifically, where and how it gets paid for, and you can’t discuss how it gets paid for until your model is sound. What are the obvious and not so obvious considerations to have when developing an alternative behavioral health delivery model? How do consistently deliver a high quality, safe and reliable experience across a range of modalities?

  • Key Takeaways:
  • Understand “alternative” therapeutic delivery models currently in operation
  • Learn how psychedelics can play their role in the delivery of service
  • Recognize the barriers, including gaining access to trained therapists that have experience with post-psychedelic treatment patients
  • Gain the perspective of behavioral health experts on the real-world impact of psychedelics on patients and what this means for future delivery models
    • Dr. Owen Muir | Chief Medical Officer, Co-Founder | Brooklyn Minds
    • Elizabeth M. Nielson, Ph.D. | Psychologist, Co-Founder | Fluence

From Silicon Valley to Psychedelics: A Case Study in Investment Opportunities in Psychedelics with MindMed

Shark Tank’s Kevin O’Leary said, “This could save lives, cure depression, help alcoholism, get people off opioids - why wouldn’t I want to be invested,” as he was discussing why he invested as part pf a $6 million funding round for MindMed. Dedicated to turning psychedelics into safe, effective and accessible medicine, MindMed is one of the pioneers in the psychedelic ecosystem and has a strategy rooted in passion, early evidence and vision to treat a variety of ailments, including addiction.

  • Key Takeaways:
  • Understand the economic model, challenges and opportunities
  • Recognize the growth and potential exit scenarios
  • Learn how to navigate economic realities in legally uncertain environment
  • JR Rahn, Co-Founder, Co-CEO| MindMed

Morning Break

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services

Understanding Economic Models for Legal Psychedelics and Psychedelic Assisted Psychotherapy While Balancing Responsibility, Opportunity, Regulations and Consumer Demand

There are various models already in existence for psychedelic based operations, but what are the advantages and disadvantages of them? From retreats to clinics, drug development to delivery - this session will provide attendees with a 360’ perspective on what existing and potential models exist for this emerging modality.

  • Key Takeaways:
  • Understand the existing economic models for psychedelics
  • Navigate the differences between production, delivery, retreat and clinic to help set your strategy
  • Envision the foreign and domestic growth opportunities and potential timeframe
    • Myles Katz, Co-Founder | Synthesis
    • Ronan Levy, Founder | Field Trip
    • Alex Speiser, COO | Orthogonal Thinker
    • Moderated by: Evan Parke, Founder | Parke PLLC

The Social, Economic and Productivity Impact of Psychedelics for Employees, Employers, Payers and Providers

While the relationship between spirituality, religion, and psychedelics has been a part of society’s dialogue and debate since its very discovery, the impact this can have for employers, employees, payers and providers is a relatively new perspective. In this session, conscious Filmmaker and entrepreneur Mike “Zappy” Zapolin shares his views on the macro impact psychedelics can have on society from his professional and personal experiences, including the making of two documentaries, “The Reality Of Truth” with Michelle Rodriguez and “Lamar Odom: Reborn” (February 2020).

  • Key Takeaways:
  • Learn what the long-term impacts on a patient's quality of care, productivity and cost to employer and payer with a psychedelic modality being incorporated into one’s health and wellness
  • Understand the cost implications for the health and workplace ecosystem can be used to form a model when evaluating the long-term impact psychedelics can have on our society
  • Mike “Zappy” Zapolin | Conscious Filmmaker | “Lamar Odom: Reborn” 2020, “The Reality Of Truth” 2017
  • In discussion with:
  • Todd Shaprio | CEO | Red Light Truffles

Morning Session Concludes

Beyond Psychiatry: Opportunities for Psychedelics as Anti-Inflammatory Medicines

Psychedelics have robust and long-lasting anti-depressant effects, and researchers are now studying whether psychedelics can treat depression specifically associated with the earliest stages of Alzheimer’s disease. However, the full therapeutic potential of psychedelics extends beyond psychiatry - some psychedelics are potently anti-inflammatory even at very low sub-perceptual doses. Aging drives and is driven by chronic inflammation and psychedelics may be particularly well-suited to treat complex diseases driven by chronic inflammation.

  • Key Takeaways:
  • Learn how Eleusis, a clinical stage life science company, confirmed low-dose LSD to be both safe and tolerable in healthy older adults
  • Understand how this company is preparing to advance both LSD and a new psychedelic drug candidate into clinical trials for age-related inflammatory disease
  • Shlomi Raz, Chairman, Founder | Eleusis

Confidence in Sourcing: Understanding the Science Behind Sample Preparation and How it can Impact the Success of Your Psychedelics Business Model

Right now anyone who is planning to launch a business involving psychedelic compounds such as psilocybin has extremely stringent standards to overcome before they can bring their products to market. Even now as the legal barriers have yet to be released, there are already numerous companies that are building business models around the production of psychedelic products. As these entities are building their business models and generating the funding to launch their companies and support their research they stand to benefit significantly from understanding the basics principles of sample preparation of a medicinal plant so that they can optimize their business strategy to include this infrastructure

  • Key Takeaways:
  • Understand how to ensure the quality of your medicine
  • Develop the strategy to build your supply chain correctly from the start
  • Navigate the legal environment to ensure purity and compliance
    • Melissa Fauth, President and CEO | Fritsch Milling & Sizing Inc.
    • Maddie Robinson, Application Consultant | Fritsch Milling & Sizing Inc.

The Investor’s Perspective Roundtable

As investment and investor interest continues to grow within the psychedelics industry, more attention is being paid to the risks and rewards of capital seekers. While the industry is still in a relatively nascent phase, the opportunity to provide potentially permanent relief to millions of people who suffer from depression, anxiety, PTS – just to name a few – is massive. How can today’s investor better understand the psychedelics landscape in order to make the most informed decision possible?

  • Key Takeaways:
  • What types of business models are most likely to attract investment?
  • What is a reasonable timeframe to expect a return?
  • Is there a different level of due diligence that must be conducted given the nature of psychedelics
  • What does a potential exit look like?
    • Amanda Eilian, Co-Founder, Partner | Able Partners
    • Richard Simon, Founder and Chair | YPO Psychedelic Medicines for Mental Health Group

The Road Ahead: What Does the Future have in Store for Psychedelics and How best can Stakeholders make Preparations Today for the Opportunities of Tomorrow?

It is universally agreed upon that psychedelics are powerful compounds, but what the most successful and productive applications are for humanity is a chapter still being written by today’s scientists and medical experts. Several barriers exist to widespread adoption including regulatory and financial, so what does the progress of late mean for the future of psychedelics? Join our distinguished panel to future cast the opportunities for psychedelics.

  • Key Takeaways:
  • Where will investment come from and how will success be managed?
  • What economic model seems most viable and poised for success?
  • What role is there for the entrepreneur, investor, life sciences and healthcare company?
  • What potential benefits to humanity might exist beyond the initial data points be collected today?
    • Mike Arnold, CEO/Founder | Silo Wellness
    • Shelby Hartman, Chief Executive Officer, Co-Founder | DoubleBlind
    • Srinivas Rao, MD, PhD, Chief Scientific Officer | ATAI Life Sciences AG
  • Moderated by: Lewis Goldberg, Managing Partner | KCSA Strategic Communications

Closing Session: Making Sense of the Opportunities

We’ve heard and saw a lot over the past few days, but where do investors and entrepreneurs go from here? How can you take what you’ve learned and who you’ve met to develop your strategy? Take a page out of one of the leaders in the psychedelics space, Orthogonal Thinker and model your game plan off of their experiences and vision.

    • Alex Speiser, COO | Orthogonal Thinker

Chair’s Closing Remarks and Virtual Happy Hour

Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.

Start your learning and networking today! Join the Psychedelic Opportunity Summit LinkedIn group at: https://www.linkedin.com/groups/13807942

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Close Bitnami banner